KMT2C mutation
|
CRC
|
KMT2C mutation
|
CRC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
KMT2C mutation
|
Solid Tumor
|
KMT2C mutation
|
Solid Tumor
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
KMT2C mutation
|
NSCLC
|
KMT2C mutation
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
KMT2C mutation
|
CRC
|
KMT2C mutation
|
CRC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
KMT2C mutation
|
HCC
|
KMT2C mutation
|
HCC
|
PD1 inhibitor + lenvatinib Sensitive: C3 – Early Trials
|
PD1 inhibitor + lenvatinib Sensitive: C3 – Early Trials
|
KMT2C mutation
|
RCC
|
KMT2C mutation
|
RCC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
KMT2C mutation
|
Melanoma
|
KMT2C mutation
|
Melanoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
KMT2C mutation
|
Bladder Cancer
|
KMT2C mutation
|
Bladder Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|